Grown Rogue forms 51/49 New York joint venture with capital partner for USD 15 million financing

• Grown Rogue formed Grown Rogue New York, a 51/49 joint venture with a capital partner, to pursue PharmaCann’s New York license and assets.
• Capital partner invested USD 10 million for 49% preferred equity; preferred can convert into subordinate voting shares starting at USD 0.55.
• Additional USD 5 million drawable term-loan commitment supports total project-based financing of up to USD 15 million for acquisition, capex, working capital.
• GRNY took interim control through a services agreement, funding up to USD 9 million secured to keep four Verilife dispensaries operating.
• Purchase price expected near USD 4.5 million, including inventory adjustment; USD 3 million payable on regulatory approval of change of control.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grown Rogue International Inc. published the original content used to generate this news brief via CNW (Ref. ID: 202608210915CANADANWCANADAPR_C8063) on August 21, 2026, and is solely responsible for the information contained therein.